Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T65755
|
||||
Former ID |
TTDC00297
|
||||
Target Name |
Histone deacetylase
|
||||
Synonyms |
HD; HDAC
|
||||
Target Type |
Successful
|
||||
Disease | Autoimmune diabetes [ICD10: E08-E13] | ||||
Cutaneous T-cell lymphoma [ICD9: 202.1, 202.2; ICD10: C84.0, C84.1] | |||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Epilepsy [ICD10: G40] | |||||
HIV-1 infection [ICD9: 001-139, 042; ICD10: B20-B24] | |||||
Keratosis [ICD10: L57.0] | |||||
Lymphoma [ICD9: 202.8, 208.9; ICD10: C81-C86] | |||||
Multiple myeloma [ICD9: 203; ICD10: C90] | |||||
Myelodysplastic syndrome; Myelofibrosis [ICD9:238.7, 208.9, 289.83, 709.2; ICD10: D46, C94.4, D47.4] | |||||
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06] | |||||
Rhinovirus infection [ICD10: J20.6?] | |||||
Spinal muscular atrophy [ICD9: 335.0-335.1; ICD10: G00-G99] | |||||
Function |
Responsible for the deacetylation of lysine residues on the n-terminal part of the core histones (H2a, H2b, H3 and H4). Histone deacetylation givesa tag for epigenetic repression and plays an important role in transcriptional regulation.
|
||||
BioChemical Class |
Carbon-nitrogen hydrolase
|
||||
Target Validation |
T65755
|
||||
EC Number |
EC 3.5.1.-
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Sodium phenylbutyrate | Drug Info | Approved | Spinal muscular atrophy | [522122] |
Valproic Acid | Drug Info | Approved | Epilepsy | [536447], [542039], [551871] | |
CMS-024-02 | Drug Info | Phase 3 | Cancer | [523721] | |
Abexinostat | Drug Info | Phase 2 | Cancer | [543092], [548180] | |
APH-0812 | Drug Info | Phase 2 | HIV-1 infection | [526936], [528914] | |
DAC-060 | Drug Info | Phase 2 | Keratosis | [548990] | |
JNJ-26481585 | Drug Info | Phase 2 | Cancer | [530481], [542523] | |
PDX-101 | Drug Info | Phase 2 | Cancer | [533034] | |
Pracinostat | Drug Info | Phase 2 | Myelodysplastic syndrome; Myelofibrosis | [543091], [548531] | |
Rocilinostat | Drug Info | Phase 2 | Multiple myeloma | [549121] | |
ACY-1215 | Drug Info | Phase 1/2 | Autoimmune diabetes | [524684], [542040] | |
CG-200745 | Drug Info | Phase 1 | Cancer | [523222] | |
CT-200 | Drug Info | Phase 1 | Cancer | [548651] | |
CXD-101 | Drug Info | Phase 1 | Cancer | [524509] | |
GSK311739 | Drug Info | Phase 1 | Rhinovirus infection | [551509] | |
GSK3117391 | Drug Info | Phase 1 | Rheumatoid arthritis | [550970] | |
SHAPE | Drug Info | Phase 1 | Lymphoma | [550089] | |
SHP-141 | Drug Info | Phase 1 | Cutaneous T-cell lymphoma | [523985] | |
CS-00028 | Drug Info | Preclinical | Cancer | [548010] | |
MKC-1313 | Drug Info | Terminated | Cancer | [548343] | |
Inhibitor | (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one | Drug Info | [526871] | ||
2,2-bis(3-fluorophenyl)-N-hydroxyacetamide | Drug Info | [530327] | |||
2,2-bis(4-chlorophenyl)-N-hydroxyacetamide | Drug Info | [530327] | |||
2,2-bis(4-fluorophenyl)-N-hydroxyacetamide | Drug Info | [530327] | |||
2-(methylsulfonylthio)ethyl 2-propylpentanoate | Drug Info | [529333] | |||
4-Benzoylamino-N-hydroxy-benzamide | Drug Info | [527691] | |||
4-Butyrylamino-N-hydroxy-benzamide | Drug Info | [526922] | |||
4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide | Drug Info | [526266] | |||
4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide | Drug Info | [527439] | |||
4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide | Drug Info | [526266] | |||
4-Phenylbutyrohydroxamic acid | Drug Info | [530700] | |||
5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide | Drug Info | [527056] | |||
5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione | Drug Info | [529333] | |||
5-Mercapto-pentanoic acid phenylamide | Drug Info | [527439] | |||
6-(2-Bromo-acetylamino)-hexanoic acid phenylamide | Drug Info | [527439] | |||
6-benzenesulfinylhexanoic acid hydroxamide | Drug Info | [527980] | |||
6-benzenesulfonylhexanoic acid hydroxamide | Drug Info | [527980] | |||
6-Mercapto-hexanoic acid phenylamide | Drug Info | [527439] | |||
6-Phenoxy-hexane-1-thiol | Drug Info | [527439] | |||
6-phenylsulfanylhexanoic acid hydroxamide | Drug Info | [527980] | |||
7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one | Drug Info | [526871] | |||
7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one | Drug Info | [526878] | |||
7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one | Drug Info | [526871] | |||
7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one | Drug Info | [526871] | |||
7-Mercapto-heptanoic acid benzothiazol-2-ylamide | Drug Info | [527439] | |||
7-Mercapto-heptanoic acid biphenyl-3-ylamide | Drug Info | [527439] | |||
7-Mercapto-heptanoic acid biphenyl-4-ylamide | Drug Info | [527439] | |||
7-Mercapto-heptanoic acid phenylamide | Drug Info | [527439] | |||
7-Mercapto-heptanoic acid pyridin-3-ylamide | Drug Info | [527439] | |||
7-Mercapto-heptanoic acid quinolin-3-ylamide | Drug Info | [527439] | |||
8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one | Drug Info | [526871] | |||
8-Mercapto-octanoic acid phenylamide | Drug Info | [527439] | |||
8-Oxo-8-phenyl-octanoic acid | Drug Info | [526266] | |||
8-Oxo-8-phenyl-octanoic acid hydroxyamide | Drug Info | [526878] | |||
9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide | Drug Info | [526878] | |||
9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one | Drug Info | [526878] | |||
APH-0812 | Drug Info | [526936], [528914] | |||
Apicidin | Drug Info | [535634], [536272], [536509] | |||
Azelaic bishydroxamic acid | Drug Info | [536272] | |||
CG-1521 | Drug Info | [536272] | |||
CG-200745 | Drug Info | [533181] | |||
CHAP1 | Drug Info | [535274], [536509] | |||
CHAP31 | Drug Info | [535274], [536509] | |||
CT-200 | Drug Info | [549783] | |||
CXD-101 | Drug Info | [530566] | |||
Cyclostellettamine derivative | Drug Info | [527058] | |||
DAC-060 | Drug Info | [544228] | |||
LBH539 | Drug Info | [537114] | |||
MKC-1313 | Drug Info | [551674] | |||
N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide | Drug Info | [530704] | |||
N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide | Drug Info | [530704] | |||
N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide | Drug Info | [530704] | |||
N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide | Drug Info | [530704] | |||
N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide | Drug Info | [529767] | |||
N-(2-aminophenyl)-4-methoxybenzamide | Drug Info | [529104] | |||
N-(2-aminophenyl)nicotinamide | Drug Info | [529767] | |||
N-(2-Ethylphenyl)-N'-hydroxyoctanediamide | Drug Info | [530704] | |||
N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide | Drug Info | [527500] | |||
N-(2-Mercapto-ethyl)-N'-phenyl-succinamide | Drug Info | [527500] | |||
N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide | Drug Info | [530704] | |||
N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide | Drug Info | [530704] | |||
N-(3-Ethylphenyl)-N'-hydroxyoctanediamide | Drug Info | [530704] | |||
N-(4-aminobiphenyl-3-yl)nicotinamide | Drug Info | [529767] | |||
N-(4-Ethylphenyl)-N'-hydroxyoctanediamide | Drug Info | [530704] | |||
N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide | Drug Info | [525643] | |||
N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide | Drug Info | [526266] | |||
N-(5-Hydroxycarbamoyl-pentyl)-benzamide | Drug Info | [525643] | |||
N-(6-Hydroxycarbamoyl-hexyl)-benzamide | Drug Info | [526266] | |||
N-(6-Mercapto-hexyl)-benzamide | Drug Info | [527439] | |||
N-hydroxy-2,2-diphenylacetamide | Drug Info | [530327] | |||
N-hydroxy-2,2-diphenylpropanamide | Drug Info | [530327] | |||
N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide | Drug Info | [527691] | |||
N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide | Drug Info | [527691] | |||
N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide | Drug Info | [527691] | |||
N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide | Drug Info | [527691] | |||
N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide | Drug Info | [527691] | |||
N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide | Drug Info | [527691] | |||
N-Hydroxy-4-(pentanoylamino-methyl)-benzamide | Drug Info | [526922] | |||
N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide | Drug Info | [526922] | |||
N-Hydroxy-4-phenylacetylamino-benzamide | Drug Info | [527691] | |||
N-hydroxy-9,10-dihydroanthracene-9-carboxamide | Drug Info | [530327] | |||
N-hydroxy-9H-xanthene-9-carboxamide | Drug Info | [530327] | |||
N-Hydroxy-N'-(2-methylphenyl)octanediamide | Drug Info | [530704] | |||
N-Hydroxy-N'-(3-methylphenyl)octanediamide | Drug Info | [530704] | |||
N-Hydroxy-N'-(4-methoxyphenyl)octanediamide | Drug Info | [530704] | |||
N-Hydroxy-N'-(4-methylphenyl)octanediamide | Drug Info | [530704] | |||
N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide | Drug Info | [530106] | |||
Octanedioic acid bis-hydroxyamide | Drug Info | [530700] | |||
Octanedioic acid hydroxyamide pyridin-2-ylamide | Drug Info | [526266] | |||
Octanedioic acid hydroxyamide pyridin-4-ylamide | Drug Info | [526266] | |||
PSAMMAPLIN A | Drug Info | [526878] | |||
Rocilinostat | Drug Info | [550471] | |||
SHAPE | Drug Info | [550090] | |||
Sodium phenylbutyrate | Drug Info | [530995], [551871] | |||
ST-2986 | Drug Info | [530016] | |||
ST-2987 | Drug Info | [530016] | |||
ST-3050 | Drug Info | [530016] | |||
ST-5732 | Drug Info | [530067] | |||
Suberic bishydroxamic acid | Drug Info | [536272] | |||
Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester | Drug Info | [527439] | |||
Trapoxin | Drug Info | [535274] | |||
Trichostatin A | Drug Info | [535661], [536509], [537490] | |||
Trifluoromethylketone | Drug Info | [536272] | |||
Valproic Acid | Drug Info | [535221], [536272], [537490], [537523], [537552] | |||
Modulator | Abexinostat | Drug Info | [533112] | ||
ACY-1215 | Drug Info | [544487] | |||
CMS-024-02 | Drug Info | [550907] | |||
GSK311739 | Drug Info | [550994] | |||
GSK3117391 | Drug Info | [544203] | |||
JNJ-26481585 | Drug Info | [542523] | |||
PDX-101 | Drug Info | [1572591] | |||
Pracinostat | Drug Info | [543091] | |||
SHP-141 | Drug Info | [550476] | |||
Antagonist | CS-00028 | Drug Info | [551918] | ||
References | |||||
Ref 522122 | ClinicalTrials.gov (NCT00533559) Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl. U.S. National Institutes of Health. | ||||
Ref 523222 | ClinicalTrials.gov (NCT01226407) Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile. U.S. National Institutes of Health. | ||||
Ref 523721 | ClinicalTrials.gov (NCT01489566) Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients. U.S. National Institutes of Health. | ||||
Ref 523985 | ClinicalTrials.gov (NCT01646567) SHP-141C in Plaque Type Psoriasis. U.S. National Institutes of Health. | ||||
Ref 524509 | ClinicalTrials.gov (NCT01977638) Phase 1 Trial of CXD101 in Patients With Advanced Cancer. U.S. National Institutes of Health. | ||||
Ref 524684 | ClinicalTrials.gov (NCT02091063) ACY-1215 for Relapsed/Refractory Lymphoid Malignancies. U.S. National Institutes of Health. | ||||
Ref 526936 | Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003;21(6):924-36. | ||||
Ref 528914 | Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62. | ||||
Ref 530481 | JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res. 2009 Nov 15;15(22):6841-51. | ||||
Ref 533034 | A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811-9. | ||||
Ref 536447 | Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. | ||||
Ref 542039 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7009). | ||||
Ref 542040 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7010). | ||||
Ref 542523 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7503). | ||||
Ref 543091 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365). | ||||
Ref 543092 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8366). | ||||
Ref 548010 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021167) | ||||
Ref 548180 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022814) | ||||
Ref 548343 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024821) | ||||
Ref 548531 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026393) | ||||
Ref 548651 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027375) | ||||
Ref 548990 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031213) | ||||
Ref 549121 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032606) | ||||
Ref 550089 | Clinical pipeline report, company report or official report of Tetralogic pharmaceuticals. | ||||
Ref 525643 | J Med Chem. 1999 Nov 4;42(22):4669-79.Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. | ||||
Ref 526266 | J Med Chem. 2002 Feb 14;45(4):753-7.Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. | ||||
Ref 526871 | Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.Heterocyclic ketones as inhibitors of histone deacetylase. | ||||
Ref 526922 | J Med Chem. 2004 Jan 15;47(2):467-74.Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. | ||||
Ref 526936 | Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003;21(6):924-36. | ||||
Ref 527056 | Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. | ||||
Ref 527058 | Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. | ||||
Ref 527439 | J Med Chem. 2005 Feb 24;48(4):1019-32.Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. | ||||
Ref 527500 | Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. | ||||
Ref 527691 | J Med Chem. 2005 Aug 25;48(17):5530-5.Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. | ||||
Ref 527980 | J Med Chem. 2006 Jan 26;49(2):800-5.Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. | ||||
Ref 528914 | Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62. | ||||
Ref 529104 | J Med Chem. 2007 Nov 15;50(23):5543-6. Epub 2007 Oct 17.Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. | ||||
Ref 529333 | Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. Epub 2008 Feb 8.New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. | ||||
Ref 529767 | Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). | ||||
Ref 530016 | Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. Epub 2009 Feb 12.N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC)inhibitors. | ||||
Ref 530067 | Bioorg Med Chem Lett. 2009 May 15;19(10):2840-3. Epub 2009 Mar 26.Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. | ||||
Ref 530106 | Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6. Epub 2009 Apr 20.Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. | ||||
Ref 530327 | Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. Epub 2009 Aug 7.Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. | ||||
Ref 530566 | Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010 Sep;16(9):1482-7. | ||||
Ref 530700 | Nat Chem Biol. 2010 Mar;6(3):238-243. Epub 2010 Feb 7.Chemical phylogenetics of histone deacetylases. | ||||
Ref 530704 | J Med Chem. 2010 Mar 11;53(5):1937-50.Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring. | ||||
Ref 530995 | Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8. | ||||
Ref 533112 | Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31. | ||||
Ref 533181 | Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379. | ||||
Ref 535221 | The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs. 2001;15(5):339-50. | ||||
Ref 535274 | Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S20-6. | ||||
Ref 535634 | Apicidin, a histone deacetylase inhibitor, induces differentiation of HL-60 cells. Cancer Lett. 2003 Jan 28;189(2):197-206. | ||||
Ref 535661 | Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood. 2003 May 1;101(9):3451-9. Epub 2003 Jan 2. | ||||
Ref 536272 | Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. | ||||
Ref 536509 | Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. | ||||
Ref 537490 | Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol Biochem Parasitol. 2009 Jun 16. | ||||
Ref 537523 | Histone Deacetylase 2 is a Key Regulator of Diabetes and Transforming Growth Factor-{beta}1-Induced Renal Injury. Am J Physiol Renal Physiol. 2009 Jun 24. | ||||
Ref 537552 | Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086. | ||||
Ref 542523 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7503). | ||||
Ref 543091 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365). | ||||
Ref 544203 | The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009 January; 10(1): 32-42. | ||||
Ref 544228 | Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Correction in: volume 4 on page 1369. | ||||
Ref 550090 | Clinical pipeline report, company report or official report of Tetralogic pharmaceuticals. | ||||
Ref 550907 | US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery. | ||||
Ref 550994 | Clinical pipeline report, company report or official report of Phrma.org Leading Chronic Diseases Affecting Seniors 2014. | ||||
Ref 551674 | ENTREMED TO ACQUIRE MIIKANA THERAPEUTICS. U.S. Securities and Exchange Commission. December 22, 2005. | ||||
Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.